MEDI 3726Alternative Names: MEDI3726
Latest Information Update: 19 Jan 2017
At a glance
- Originator MedImmune
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 20 Dec 2016 MedImmune plans a phase I trial for Prostate cancer in USA, United Kingdom and Switzerland (NCT02991911)
- 01 Dec 2016 Phase-I clinical trials in Prostate cancer (Second-line therapy or greater, Metastatic disease) in USA (unspecified route) (NCT02991911)